{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+1-4+tablets+daily&page=3",
    "query": {
      "intervention": "Placebo 1-4 tablets daily",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 869,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+1-4+tablets+daily&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+1-4+tablets+daily&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T04:12:17.897Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00743795",
      "title": "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "GS-9190",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Alfa 2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 252,
      "start_date": "2008-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 48,
      "location_summary": "Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Clemente",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743795"
    },
    {
      "nct_id": "NCT07767903",
      "title": "A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "SEP-363856",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 384,
      "start_date": "2026-08-06",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 5,
      "location_summary": "Redlands, California • Orlando, Florida • Cherry Hill, New Jersey + 2 more",
      "locations": [
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        },
        {
          "city": "Jamaica",
          "state": "New York"
        },
        {
          "city": "Everett",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07767903"
    },
    {
      "nct_id": "NCT04046939",
      "title": "Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Asthma",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dexpramipexole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Knopp Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 534,
      "start_date": "2019-08-15",
      "completion_date": "2021-03-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 36,
      "location_summary": "Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046939"
    },
    {
      "nct_id": "NCT00110799",
      "title": "SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic",
        "Hepatitis C",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "SB497115",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2005-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-06-04",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110799"
    },
    {
      "nct_id": "NCT05113745",
      "title": "A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Narcolepsy",
        "Cataplexy",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "AXS-12 (reboxetine)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axsome Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2021-10-20",
      "completion_date": "2024-11-15",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05113745"
    },
    {
      "nct_id": "NCT00097591",
      "title": "A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Arteriosclerosis",
        "Acute Coronary Syndromes"
      ],
      "interventions": [
        {
          "name": "Prasugrel",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13619,
      "start_date": "2004-11",
      "completion_date": "2007-07",
      "has_results": true,
      "last_update_posted_date": "2010-09-16",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097591"
    },
    {
      "nct_id": "NCT02166346",
      "title": "Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transverse Myelitis",
        "Neuromyelitis Optica",
        "Idiopathic Transverse Myelitis",
        "Myelitis NOS"
      ],
      "interventions": [
        {
          "name": "Dalfampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-02",
      "completion_date": "2017-01-08",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166346"
    },
    {
      "nct_id": "NCT04518410",
      "title": "ACTIV-2: A Study for Outpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "bamlanivimab 7000mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196+BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "BMS-986414 + BMS-986413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (3,840 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (10,240 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB + IMDEVIMAB",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 7000mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 700mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BRII-196+BRII-198",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986414 + BMS-986413",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (high dose)",
          "type": "DRUG"
        },
        {
          "name": "bamlanivimab 700mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4044,
      "start_date": "2020-08-19",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 207,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518410"
    },
    {
      "nct_id": "NCT01677910",
      "title": "TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "Telotristat etiprate",
          "type": "DRUG"
        },
        {
          "name": "Placebo-matching telotristat etiprate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2013-01-08",
      "completion_date": "2016-03-21",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Palo Alto, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677910"
    },
    {
      "nct_id": "NCT00089843",
      "title": "Bone Loss in Women With Anorexia Nervosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Anorexia Nervosa"
      ],
      "interventions": [
        {
          "name": "Testosterone",
          "type": "DRUG"
        },
        {
          "name": "Actonel (risedronate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Actonel (risedronate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo testosterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2003-06",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-08T04:12:17.897Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089843"
    }
  ]
}